TGFB INHIBITORS AND USE THEREOF
Disclosed herein are novel inhibitors of TGFβ1 activation with durable inhibitory effects. Methods directed to the selection of a suitable TGFβ inhibitor for various disease conditions and patient populations are also provided.
1 . An isoform-selective inhibitor of TGFβ1 activation,
wherein the inhibitor is a monoclonal antibody or an antigen-binding fragment thereof, which selectively inhibits TGFβ1 activation;
wherein the monoclonal antibody or the antigen-binding fragment thereof binds each of human LTBP1-proTGFβ1 and/or human LTBP3-proTGFβ1 with a monovalent dissociation rate of 10.0e-4 (1/s) as measured by a surface plasmon resonance (SPR)-based assay, and optionally with a K D of <1.0 nM; and,
wherein the monoclonal antibody or the antigen-binding fragment thereof comprises the following six CDRs:
i) an H-CDR1 comprising GFTFADYA (SEQ ID NO: 276);
ii) an H-CDR2 comprising ISGSG(X 1 )AT, wherein optionally the X 1 is A or K (SEQ ID NO: 277);
iii) an H-CDR3 comprising VSSG(X 1 )WD(X 2 )D, wherein optionally X 1 is H, D or Q; and
wherein further optionally X 2 is F or Y (SEQ ID NO: 278);
iv) an L-CDR1 comprising QSISSY (SEQ ID NO: 279);
v) an L-CDR2 comprising AAS(X 1 )(X 2 )(X 3 )(X 4 ), wherein optionally X 1 is N, G or V;
wherein further optionally X 2 is L, N or E; wherein further optionally X 3 is Q or E; and
wherein further optionally X 4 is S or T (SEQ ID NO: 280); and,
vi) an L-CDR3 comprising QQTY(X 1 )VPLT, wherein optionally X 1 is T or G (SEQ ID NO: 281).
2 . The isoform-selective inhibitor of claim 1 , wherein:
i) the H-CDR1 comprises GFTFADYA (SEQ ID NO: 276);
ii) the H-CDR2 comprises ISGSGAAT (SEQ ID NO: 282);
iii) the H-CDR3 comprises VSSG(X 1 )WD(X 2 )D, wherein optionally the X 1 is H or Q, and X 2 is Y or F (SEQ ID NO: 283);
iv) the L-CDR1 comprises QSISSY (SEQ ID NO: 279);
v) the L-CDR2 comprises AASGLES (SEQ ID NO: 284); and,
vi) the L-CDR3 comprises QQTYGVPLT (SEQ ID NO: 285).
3 . The isoform-selective inhibitor of claim 1 , wherein:
i) the H-CDR1 comprises GFTFADYA (SEQ ID NO: 276);
ii) the H-CDR2 comprises ISGSGAAT (SEQ ID NO: 282);
iii) the H-CDR3 comprises VSSGHWDFD (SEQ ID NO: 289);
iv) the L-CDR1 comprises QSISSY (SEQ ID NO: 279);
v) the L-CDR2 comprises AASNLES (SEQ ID NO: 292); and,
vi) the L-CDR3 comprises QQTYTVPLT (SEQ ID NO: 296).
4 . The isoform-selective inhibitor of claim 1 , wherein:
i) the H-CDR1 comprises GFTFADYA (SEQ ID NO: 276);
ii) the H-CDR2 comprises ISGSGAAT (SEQ ID NO: 282);
iii) the H-CDR3 comprises VSSGHWDFD (SEQ ID NO: 289);
iv) the L-CDR1 comprises QSISSY (SEQ ID NO: 279);
v) the L-CDR2 comprises AASGLES (SEQ ID NO: 284); and,
vi) the L-CDR3 comprises QQTYTVPLT (SEQ ID NO: 296).
5 . The isoform-selective inhibitor of claim 1 , wherein:
i) the H-CDR1 comprises GFTFADYA (SEQ ID NO: 276);
ii) the H-CDR2 comprises ISGSGAAT (SEQ ID NO: 282);
iii) the H-CDR3 comprises VSSGHWDFD (SEQ ID NO: 289);
iv) the L-CDR1 comprises QSISSY (SEQ ID NO: 279);
v) the L-CDR2 comprises AASVNES (SEQ ID NO: 293); and,
vi) the L-CDR3 comprises QQTYTVPLT (SEQ ID NO: 296).
6 . The isoform-selective inhibitor of claim 1 , wherein:
i) the H-CDR1 comprises GFTFADYA (SEQ ID NO: 276);
ii) the H-CDR2 comprises ISGSGAAT (SEQ ID NO: 282);
iii) the H-CDR3 comprises VSSGHWDFD (SEQ ID NO: 289);
iv) the L-CDR1 comprises QSISSY (SEQ ID NO: 279);
v) the L-CDR2 comprises AASNEET (SEQ ID NO: 294); and,
vi) the L-CDR3 comprises QQTYTVPLT (SEQ ID NO: 296).
7 . The isoform-selective inhibitor of claim 1 , wherein:
i) the H-CDR1 comprises GFTFADYA (SEQ ID NO: 276);
ii) the H-CDR2 comprises ISGSGAAT (SEQ ID NO: 282);
iii) the H-CDR3 comprises VSSGHWDFD (SEQ ID NO: 289);
iv) the L-CDR1 comprises QSISSY (SEQ ID NO: 279);
v) the L-CDR2 comprises AASNLES (SEQ ID NO: 292); and,
vi) the L-CDR3 comprises QQTYGVPLT (SEQ ID NO: 285).
8 . The isoform-selective inhibitor of claim 1 , wherein:
i) the H-CDR1 comprises GFTFADYA (SEQ ID NO: 276);
ii) the H-CDR2 comprises ISGSGAAT (SEQ ID NO: 282);
iii) the H-CDR3 comprises VSSGHWDFD (SEQ ID NO: 289);
iv) the L-CDR1 comprises QSISSY (SEQ ID NO: 279);
v) the L-CDR2 comprises AASGLES (SEQ ID NO: 284); and,
vi) the L-CDR3 comprises QQTYGVPLT (SEQ ID NO: 285).
9 . The isoform-selective inhibitor of claim 1 , wherein:
i) the H-CDR1 comprises GFTFADYA (SEQ ID NO: 276);
ii) the H-CDR2 comprises ISGSGAAT (SEQ ID NO: 282);
iii) the H-CDR3 comprises VSSGHWDYD (SEQ ID NO: 287);
iv) the L-CDR1 comprises QSISSY (SEQ ID NO: 279);
v) the L-CDR2 comprises AASNLES (SEQ ID NO: 292); and,
vi) the L-CDR3 comprises QQTYTVPLT (SEQ ID NO: 296).
10 . The isoform-selective inhibitor of claim 1 , wherein:
i) the H-CDR1 comprises GFTFADYA (SEQ ID NO: 276);
ii) the H-CDR2 comprises ISGSGAAT (SEQ ID NO: 282);
iii) the H-CDR3 comprises VSSGHWDYD (SEQ ID NO: 287);
iv) the L-CDR1 comprises QSISSY (SEQ ID NO: 279);
v) the L-CDR2 comprises AASGLES (SEQ ID NO: 284); and,
vi) the L-CDR3 comprises QQTYTVPLT (SEQ ID NO: 296).
11 . The isoform-selective inhibitor of claim 1 , wherein:
i) the H-CDR1 comprises GFTFADYA (SEQ ID NO: 276);
ii) the H-CDR2 comprises ISGSGAAT (SEQ ID NO: 282);
iii) the H-CDR3 comprises VSSGHWDYD (SEQ ID NO: 287);
iv) the L-CDR1 comprises QSISSY (SEQ ID NO: 279);
v) the L-CDR2 comprises AASNLES (SEQ ID NO: 292); and,
vi) the L-CDR3 comprises QQTYGVPLT (SEQ ID NO: 285).
12 . The isoform-selective inhibitor of claim 1 , wherein:
i) the H-CDR1 comprises GFTFADYA (SEQ ID NO: 276);
ii) the H-CDR2 comprises ISGSGAAT (SEQ ID NO: 282);
iii) the H-CDR3 comprises VSSGHWDYD (SEQ ID NO: 287);
iv) the L-CDR1 comprises QSISSY (SEQ ID NO: 279);
v) the L-CDR2 comprises AASGLES (SEQ ID NO: 284); and,
vi) the L-CDR3 comprises QQTYGVPLT (SEQ ID NO: 285).
13 . The isoform-selective inhibitor of claim 1 , wherein:
i) the H-CDR1 comprises GFTFADYA (SEQ ID NO: 276);
ii) the H-CDR2 comprises ISGSGAAT (SEQ ID NO: 282);
iii) the H-CDR3 comprises VSSGDWDYD (SEQ ID NO: 290);
iv) the L-CDR1 comprises QSISSY (SEQ ID NO: 279);
v) the L-CDR2 comprises AASNLES (SEQ ID NO: 292); and,
vi) the L-CDR3 comprises QQTYGVPLT (SEQ ID NO: 285).
14 . The isoform-selective inhibitor of claim 1 , wherein:
i) the H-CDR1 comprises GFTFADYA (SEQ ID NO: 276);
ii) the H-CDR2 comprises ISGSGAAT (SEQ ID NO: 282);
iii) the H-CDR3 comprises VSSGDWDYD (SEQ ID NO: 290);
iv) the L-CDR1 comprises QSISSY (SEQ ID NO: 279);
v) the L-CDR2 comprises AASGLES (SEQ ID NO: 284); and,
vi) the L-CDR3 comprises QQTYGVPLT (SEQ ID NO: 285).
15 . The isoform-selective inhibitor of claim 1 , wherein:
i) the H-CDR1 comprises GFTFADYA (SEQ ID NO: 276);
ii) the H-CDR2 comprises ISGSGAAT (SEQ ID NO: 282);
iii) the H-CDR3 comprises VSSGQWDYD (SEQ ID NO: 291);
iv) the L-CDR1 comprises QSISSY (SEQ ID NO: 279);
v) the L-CDR2 comprises AASNLES (SEQ ID NO: 292); and,
vi) the L-CDR3 comprises QQTYGVPLT (SEQ ID NO: 285).
16 . The isoform-selective inhibitor of claim 1 , wherein:
i) the H-CDR1 comprises GFTFADYA (SEQ ID NO: 276);
ii) the H-CDR2 comprises ISGSGAAT (SEQ ID NO: 282);
iii) the H-CDR3 comprises VSSGQWDYD (SEQ ID NO: 291);
iv) the L-CDR1 comprises QSISSY (SEQ ID NO: 279);
v) the L-CDR2 comprises AASGLES (SEQ ID NO: 284); and,
vi) the L-CDR3 comprises QQTYGVPLT (SEQ ID NO: 285).
17 . The isoform-selective inhibitor of claim 1 , wherein:
i) the H-CDR1 comprises GFTFADYA (SEQ ID NO: 276);
ii) the H-CDR2 comprises ISGSGKAT (SEQ ID NO: 288);
iii) the H-CDR3 comprises VSSGDWDYD (SEQ ID NO: 290);
iv) the L-CDR1 comprises QSISSY (SEQ ID NO: 279);
v) the L-CDR2 comprises AASNLQS (SEQ ID NO: 295); and,
vi) the L-CDR3 comprises QQTYTVPLT (SEQ ID NO: 296).
18 . The isoform-selective inhibitor of claim 1 , wherein:
i) the H-CDR1 comprises GFTFADYA (SEQ ID NO: 276);
ii) the H-CDR2 comprises ISGSGKAT (SEQ ID NO: 288);
iii) the H-CDR3 comprises VSSGDWDYD (SEQ ID NO: 290);
iv) the L-CDR1 comprises QSISSY (SEQ ID NO: 279);
v) the L-CDR2 comprises AASGLES (SEQ ID NO: 284); and,
vi) the L-CDR3 comprises QQTYGVPLT (SEQ ID NO: 285).
19 . The isoform-selective inhibitor of claim 1 , wherein:
i) the H-CDR1 comprises GFTFADYA (SEQ ID NO: 276);
ii) the H-CDR2 comprises ISGSGAAT (SEQ ID NO: 282);
iii) the H-CDR3 comprises VSSG(H/D/Q)WD(F/Y)D (SEQ ID NO: 278);
iv) the L-CDR1 comprises QSISSY (SEQ ID NO: 279);
v) the L-CDR2 comprises AAS(G/N)LES (SEQ ID NO: 303); and,
vi) the L-CDR3 comprises QQTY(G/T)VPLT (SEQ ID NO: 281).
20 . A method of making a pharmaceutical composition comprising an isoform-selective inhibitor of TGFβ1 activation, the method comprising the steps of:
i) selecting an antibody or an antigen-binding fragment thereof that selectively binds a human latent TGFβ1 complex with a sub-nanomolar affinity (K D <1.0 nM) and with a dissociation rate of <10×10 −4 (k OFF <10.0E-4) as measured by an in vitro binding assay (e.g., BLI- or SPR-based technique) with Fab fragments and inhibits activation of TGFβ1 in a cell-based potency assay;
ii) producing the antibody or an engineered construct comprising an antigen-binding fragment of the antibody, in a cell culture, wherein optionally the cell culture is a mammalian cell culture, and wherein further optionally the cell culture has a volume of ≥250 L;
iii) formulating the antibody or the antigen-binding fragment thereof into a pharmaceutical composition comprising the inhibitor and a pharmaceutically acceptable excipient.
21 . The method of claim 20 , wherein the antibody or the antigen-binding fragment thereof binds human LTBP1-proTGFβ1 or human LTBP3-proTGFβ1.
22 . The method of claim 20 , wherein the antibody or the antigen binding fragment thereof binds human LTBP1-proTGFβ1, human LTBP3-proTGFβ1, human GARP-proTGFβ1 and LRRC33-proTGFβ1.
23 . A pharmaceutical composition made by the process according to any one of claims 20 - 22 .
24 . The isoform-selective inhibitor of TGFβ1 according to any one of claims 1 - 19 for use in the treatment of a fibrotic disorder in a subject.
25 . The isoform-selective inhibitor of TGFβ1 according to any one of claims 1 - 19 for use in a method of decreasing the levels of circulating latent TGFβ in the subject.
26 . The isoform-selective inhibitor of TGFβ1 according to claim 25 , wherein the level of circulating latent TGFβ is determined in a sample obtained from the subject.
27 . The isoform-selective inhibitor of TGFβ1 according to claim 26 , wherein the sample is a whole blood sample or a blood component.
28 . The isoform-selective inhibitor of TGFβ1 according to claim 25 , wherein the circulating latent TGFβ is circulating latent TGFβ1.
29 . Use of the isoform-selective inhibitor of TGFβ1 according to any one of claims 1 - 19 in the manufacture of a medicament comprising the antibody or the antigen-binding fragment thereof and a pharmaceutically acceptable excipient.
30 . A method of treating a disease involving extracellular matric (ECM) dysregulation in a subject, the method comprising steps of:
selecting a TGFβ inhibitor that inhibits TGFβ1 but does not inhibit one or both of TGFβ2 and/or TGFβ3;
administering to a subject having a disease involving ECM dysregulation the TGFβ inhibitor in an amount effective to treat the disease, wherein optionally the disease is a fibrosis or cancer, wherein further optionally the cancer comprises a solid tumor or the cancer is a myeloproliferative disorder.
31 . A method of treating fibrosis in a subject, the method comprising steps of
selecting a TGFβ inhibitor that inhibits TGFβ1 but does not inhibit one or both of TGFβ2 and TGFβ3;
administering to a subject having a fibrotic condition the TGFβ inhibitor in an amount effective to treat the fibrotic condition.
32 . The method of claim 31 , wherein the fibrotic condition is liver fibrosis, kidney fibrosis, cardiac fibrosis or lung fibrosis.
33 . The method of claim 32 , wherein the fibrotic condition is liver fibrosis associated with NASH.
34 . The method of claim 33 , wherein the liver fibrosis is stage 3 or stage 4 fibrosis.
35 . The method of claim 31 , further comprising the steps of:
(i) determining the levels of circulating latent TGFβ in the subject prior to administering the TGFβ inhibitor; and
(ii) determining the levels of circulating latent TGFβ in the subject after administering the TGFβ inhibitor,
wherein an increase in circulating latent TGFβ after inhibitor administration, as compared to circulating latent TGFβ before administration, indicates therapeutic efficacy.
36 . An isolated monoclonal antibody or an antigen-binding fragment thereof, which selectively inhibits TGFβ1 activation, comprising:
a heavy chain complementary determining region 1 (CDRH1) comprising GFTFADYA (SEQ ID NO: 276);
a heavy chain complementary determining region 2 (CDRH2) comprising ISGSGAAT (SEQ ID NO: 282);
a heavy chain complementary determining region 3 (CDRH3) comprising VSSGHWDYD (SEQ ID NO: 287);
a light chain complementary determining region 1 (CDRL1) comprising QSISSY (SEQ ID NO: 279);
a light chain complementary determining region 2 (CDRL2) comprising AASGLES (SEQ ID NO: 284); and,
a light chain complementary determining region 3 (CDRL3) comprising QQTYGVPLT (SEQ ID NO: 285).
37 . An isolated monoclonal antibody or an antigen-binding fragment thereof, comprising a heavy chain variable domain (VH) and a light chain variable domain (VL), wherein, the VH comprises a sequence having at least 95% identity to EVQLLESGGGLVQPGGSLRLSCAASGFTFADYAMTWVRQAPGKGLEVWSAISGSGAATYFADSVK GRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARVSSGHWDYDYWGQGTLVTVSS (SEQ ID NO: 297), and wherein the VL comprises a sequence having at least 95% identity to DIQLTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASGLESGVPSRFSGSGSG TDFTLTISSLQPEDFATYYCQQTYGVPLTFGGGTKVEIK (SEQ ID NO: 298).
38 . The isolated monoclonal antibody or antigen-binding fragment thereof of claim 36 or claim 37 , wherein, the VH comprises EVQLLESGGGLVQPGGSLRLSCAASGFTFADYAMTWVRQAPGKGLEWVSAISGSGAATYFADSVK GRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARVSSGHWDYDYWGQGTLVTVSS (SEQ ID NO: 297), and wherein the VL comprises DIQLTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASGLESGVPSRFSGSGSG TDFTLTISSLQPEDFATYYCQQTYGVPLTFGGGTKVEIK (SEQ ID NO: 298).